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Abstract
Deletions of the long arm of chromosome 9, del(9)(q22), are rare aberrations specifi- 
cally found in acute myeloid leukemia (AML). Yamamoto et al, 1999, reported the 
first case of acute promyelocytic leukemia (APL) with a terminal 9q deletion as a sole 
abnormality. Here we describe the second case with the same aberration, the patient, 
an eleven-years-old girl with APL. Chromosomal analysis by the Giemsa R-banding 
technique and FISH using BCR/ABL and PML/RARA probe on short-term cell cultures 
from bone marrow was performed. A deletion of a 9 chromosome, del(9)(q22) was 
detected. Deletions of 9q have been described in about 3% to 4% of the AML patients, 
especially in M1 and M2 myeloid leukemia. Sole 9q terminal deletions, are less common 
than interstitial ones and involve q21~q22 band predominantly. A recent study suggests 
that 9q deletion, even in the absence of t(15;17), shows a relatively good prognosis. 
However, our patient died during the treatment. 
Análisis citogenético y FISH de la deleción terminal del brazo largo del cromosoma 
9 en un paciente con leucemia promielocítica aguda 
Resumen
Las deleciones del brazo largo del cromosoma 9, del(9)(q22), son raras, y se observan 
específicamente en la Leucemia Mieloide Aguda (LMA). Yamamoto et al., 1999, publico 
el primer caso de leucemia promielocítica aguda (LPA) con un deleción terminal 9q, 
como la única aberración cromosómica presente. Aquí nosotros describimos el segundo 
caso con la misma aberración. El paciente, una mujer de 11 años de edad con LPA. 
El análisis cromosómico fue realizado  en cultivos celulares de medula ósea usando la 
técnica de bandas R con Giemsa y FISH con sondas para detectar las fusiones BCR/ABL 
y PML/RARA. Fue identificada la deleción de una copia del cromosoma 9, del(9)(q22). 
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Introduction
According to FAB classification (French - American - British 
cooperative group), acute promyelocytic leukemia (APL) is 
defined as an acute myeloid leukemia (AML) subtype M3.1 
APL is distinguished from other acute myeloid leukemias 
(AMLs) by cytogenetic, clinical, and also biological charac-
teristics,2-6 Although the basis of the diagnosis remains in 
the morphological characteristics, additional studies in-
cluding immunophenotyping, cytogenetic evaluation, and 
molecular genetic analysis have become critical, and in 
some specific cases mandatory and complementary tools.4 
APL typically carries a specific reciprocal chromoso-
me translocation t(15;17) in the 95% of cases, leading to 
the expression of a leukemic-generating fusion protein, 
PML-RARα.2,5,6 The APL molecular defect was found to 
be the disruption of the alpha receptor of retinoid acid 
(RARα) and its reciprocal, in frame fusion, with one of 
five partner genes: PML, located in chromosome 15q22, 
PLZF in 11q23, NuMA in 11q13, NPM in 5q32 and STAT5b 
in 17q11.2.5 The cytogenetic abnormality in rare cases 
involves reciprocal translocations of chromosomes 5, 6, 
7, 8, 11, 13, 19 and deletion (9q-).5 
Terminal deletions of the long arm of chromosome 9, 
del (9q22-ter), are rare structural aberrations specifically 
found in AML.7 Yamamoto et al, reported the first case 
of APL with a terminal 9q deletion as sole abnormality.8 
Here we describe the second case with the same structu-
ral aberration. 
Case report
An eleven years old girl was admitted to the Pablo Tobón 
Uribe Hospital, Medellín, Colombia, in February 2000 with 
severe fatigue, and fever. Physical examination showed 
fever, tachycardia, pallor, weight loss, hepatomegaly and 
splenomegaly. Blood analysis revealed a hemoglobin level 
of 8.8g/dL, platelet count 12x109/L, and white blood cells 
count of 55.2 x 10 9/ul with 12% neutrophils, 15% lympho-
cytes, and 71% blasts, diagnostic of acute leukemia. Exa-
mination of the bone marrow showed myeloid blasts (40%) 
Figure 1. R-banded karyotype of the patient: 46,XX,del(9)(q22). The arrowhead indicates del(9)(q22)
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Han sido descritas deleciones del brazo 9q en un ~ 3 a 4%, de pacientes con LMA, es-
pecialmente en los subtipos M1 y M2. La deleción terminal 9q, es menos frecuente que 
las deleciones intersticiales, y  usualmente involucra las bandas q21~q22. Un estudio 
reciente sugiere que la deleción terminal 9q, aun en la ausencia de la traslocación 
entre los cromosomas 15 y 17, t(15;17), confiere relativamente un buen pronóstico. 
Sin embargo, nuestro paciente falleció durante el tratamiento.  
Cytogenetic analysis and FISH of terminal deletion of the long arm of chromosome 9 195
Materials and methods
Chromosome analysis
Chromosomal analysis was performed on unstimulated 
24-hours in vitro culture of a bone marrow specimen by 
the Giemsa R banding technique. Thirty metaphases and 
300 nuclei were analyzed. Karyotype was described ac-
cording to the International System for Human Cytogene-
tic Nomenclature.9
Fluorescence in situ hybridization (FISH) 
analysis
FISH to interphase nuclei and metaphase chromosomes 
was performed at the cytogenetics laboratories of Colum-
bia University and UCLA, using a Locus Specific Identifier 
BCR/ABL Dual Color-Dual Fusion and PML/RARA Translo-
cation Probe (Vysis, Inc.).
Results
Chromosome analysis
Chromosome analysis of bone marrow cells showed 
46,XX,del(9)(q22.3) in all 30 metaphases (figure 1).
Fluorescence in situ hybridization (FISH) analysis 
FISH analysis to interphase nuclei and metaphase chro-
mosomes revealed del (9)(q22) as shown by the absence 
of one signal on chromosome 9 (figure 2).
FISH analysis to interphase nuclei revealed no PML-
RARA rearangement (figure 3).
Discussion 
In this study, R-banding and chromosome painting analy-
ses showed both normal chromosome 9, and del(9) 
(q22). Deletions of the long arm of chromosome 9, del(9)(q22), 
are rare structural aberrations specifically   found in acute 
myeloid leukemia (AML) as a sole chromosomal abnormality 
or as a  secondary change, particularly together with trans-
locations as t(8;21)(q22;q22).10 Terminal deletions of 9q are 
less common than interstitial ones and involve 9q21~9q22 
as observed in this case.10 The most common breakpoints 
proximal and distal present in the interstitial deletions are 
9q21 and 9q22 respectively.11 Deletions 9q__ occurs predo-
minantly in APL subtype M1 and M2, but only seven cases of 
APL with 9q__ deletions have been reported to date.7 Yama-
moto et al., reported the first case of APL with a terminal 
deletion of 9q__ as sole chromosomal abnormality.8 Our study 
is the second case with the same abnormality.
Chromosomal rearrangements in addition to t(15;17) 
have been reported in 25%-40% of APL.3,12-19 The most fre-
quent additional change was trisomy 8.  Other abnormalities 
were far less frequent and usually involved chromosome 9, 
17, 7, 21, 16, 6 and 12. The prognostic value of those addi-
tional cytogenetic abnormalities in APL patients remains 
controversial: Hiorns et al, found them to be associated 
with a poorer prognosis, Schoch et al, and Grimwalde et al., 
found them to be associated with a similar prognosis and 
Slack et al, with a slightly better prognosis.10,14,16,19 
Figure 2.  Fluorescence in situ hybridization analysis, using 
the dual –color, dual-fusion t(9:22) DNA probe. Locus Specific 
Identifier (LSI) BCR locus/22q11.2 (green signal), is present 
in the two normal chromosomes 22. LSI ABL locus /9q34 (red 
signal) is present in the normal chromosome 9. No red signal 
is detected in the chromose 9 with terminal deletion of the 
long arm 
Figure 3.  Fluorescence in situ hybridization analysis, using 
the dual–color, dual-fusion t(15;17) DNA probe. The cells 
in this image show the two orange (PML), two green (RARA) 
normal signal pattern. No fusion signals were detected
and atypical promyelocytes (35%). Cell suspension immu-
nophenotypic studies were performed using CD3, CD13, 
CD19, CD33 and myeloperoxidase (MPO) reaction. Studies 
were positive for CD13, CD33 and MPO and negative for 
CD3 and CD19. According to FAB classification, a diagnosis 
of APL (AML M3) was made. Normal biochemistry liver and 
kidney was found. The patient was treated initially with 
cytarabine and mercaptanopurine. Four months after the 
diagnosis of APL, the patient was admitted to the Intensive 
Care Unit (ICU) with diagnosis of sepsis by Escherichia coli 
and secondary myocardial dysfunction. Finally, she died in 
ICU due to ventricular fibrillation. 
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As shown in table 1, nine cases of APL with 9q _ have 
been reported.8 All but the last two cases had t(15;17) 
and  five of them had terminal deletions. No specific 
morphological feature has been reported in APL with 
9q_.20 Survival in five of these cases seems to be very 
short, although four cases were treated without ATRA. 
FISH performed in our patient with a DNA probe flanking 
the breakpoints of t(15;17) did no show the retinoic acid 
receptor alpha (RARA*)/PML fusion signal usually gene-
rated on the der(17)t(15;17) (figure 3).  This result does 
not exclude the diagnosis of APL. It is possible that this 
patient had a cryptic chromosome rearrangement unde-
tectable by karyotype and FISH analysis. This is known to 
occur in approximately 1% of APL cases.21 In such cases, 
reverse-transcriptase PCR, RT-PCR, is the best test to 
perform with a detection sensitivity of ~1 in 105 cells 
compare to the 1% sensitivity of FISH. Unfortunately, RT-
PCR analysis was not performed in our patient. At the 
time of diagnosis this test was not available for clinical 
diagnosis. Nowadays, it is widely available, not only to 
identify a PML-RARA fusion due to a cryptic rearrange-
ment in patients with flow cytometric and bone marrow 
morphology features characteristic of APL but also to 
follow up patients for minimal residual disease.22 A fresh 
sample for RNA extraction is needed to perform the RT-
PCR, however, this is not available in our case. 
The present patient did not respond to chemoterahpy 
with cytarabine and mercaptanopurine and died in the 
course of the treatment four months after the diagnosis 
of APL. Therefore, our report suggests that 9q_ may also 
be an adverse prognostic factor in APL subtype AML, M3. 
More cases need to be investigated to elucidate the pre-
cise role of 9q_ in the pathogenesis of APL and its clinical 
significance.
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